Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2009
  • Online publication date: October 2009

13 - Oral and Parenteral Opioid Analgesics for Acute Pain Management

from SECTION II - Clinical Analgesia

Related content

Powered by UNSILO


1. Reisine T, Pasternak G. Opioid analgesics and antagonists. In Goodman LS, Gilman A, eds. The Pharmacologic Basis of Therapeutics. 9th ed. New York, NY: Macmillan; 1997.
2. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2002:569–619.
3. Pasero C, Portenoy RK, McCaffery M. Opioid analgesics. In: McCaffery M, Pasero C, eds. Pain Clinical Manual. St. Louis, MO: Mosby Inc, 1999:161–299.
4. Sinatra RS. Opioid analgesics in primary care: challenges and new advances in the management of noncancer pain. Journal of the American Board of Family Medicine. 2006;19(2):165–177.
5. Meldrum ML. A capsule history of pain management. JAMA. 2003;290:2470–2475.
6. Gilson AM, Joranson DE. Controlled substances and pain management: changes in knowledge and attitudes of state medical regulators. J Pain Symptom Manage. 2001;21:227–237.
7. Gilson AM, Joranson DE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in in patients with addictive disease. Clin J Pain. 2002;18:S91–S98.
8. American Society of Anesthesiologists. A report by the American Society of Anesthesiologists Task Force on Pain Management, Chronic Pain Section. Anesthesiology. 1997;86:995–1004.
9. Joint Commission on Accreditation of Healthcare Organizations. JCAHO Standards for Pain Management [referenced from the Comprehensive Accreditation Manual for Hospitals, Update 3, 1999 (effective January 1, 2001)]. Available at: // Accessed August 5, 2003.
10. Kweder SL. USFDA Statement before Subcommittee on criminal justice, drug abuse, and human resources. Available at: // abuse.0726. Accessed July 26, 2006.
11. Sinatra RS, Bigham M: The anatomy and pathophysiology of acute pain. In: Grass JA, ed. Problems in Anesthesiology. Vol. 10. Philadelphia, PA: Lippincott-Raven; 1997:8–22.
12. Bonica JJ. Biochemistry and modulation of nociception and pain. In: Bonica, JJ, ed. The Management of Pain. 2nd ed. Philadelphia, PA: Lea & Febiger; 1990:94–121.
13. Beecher H. Pain in men wounded in battle. Ann Surg. 1946;123:96–105.
14. Way WL, Fields HL, Schumaker MA. Chapter 31- Opioid Analgesics. In: Katsung BG, ed. Basic & Clinical Pharmacology. 9th ed. New York, NY: Lange Medical Books/McGraw-Hill; 2004.
15. Zastrow M, Svingos A, Haberstock H, et al. Regulatory endocytosis of opioid receptors: cellular mechanisms and proposed role in physiological adaptation to opiate drugs. Curr Opin Neurobiol. 2003;13:348–353.
16. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63.
17. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570–587.
18. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain. 1992;49:87–91.
19. Mogil JS. The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proc Natl Acad Sci USA. 1999;96:7744–7751.
20. Pan YX, Xu J, Bolan E, Moskowitz HS, Pasternak GW. Identification of four novel exon 5 splice variants of the mouse mu opioid receptor gene. Mol Pharmacol. 2005;68:866–875.
21. Uhl GR, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA. 1999;96:7752–7755.
22. Chou WY, Yang LC, Lu HF, Ko JY, Wang CH, Lin SH, Lee TH, Concejero A, Hsu CJ. Association of μ-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty Acta Anaesth Scand. 2006;50:787–792.
23. Reyes Gibby CC, Shete S, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain; OPRM1 and COMT gene. Pain. 2007;130:25–30.
24. Klepstad P, Dale O, Skorpen F, et al. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005;49:902–908.
25. Park HJ, Shinn HK, Lee HS et al. Genetic polymorphism in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharm Therapeut. 2007;81:539–546.
26. Hamabe W, Maeda T, Fukazawa Y, et al. Polymorphism in the ABCB1 transporter. Pharmacol Biochem Behav. 2006:85:629–636.
27. Ross JR, et al. Pharmacogenetics J. 2005;5:324–336. Goodman & Gilman's Pharmacology. 11th ed. McGraw-Hill. 2006.
28. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856–1866.
29. Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102–105.
30. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Sympt Manag. 1996;11:203–217.
31. Gan TJ, Ginsberg B, Glass PSA, et al. Opioid sparing effects of a low-dose infusion of naloxone in patient administered morphine sulphate. Anesthesiology. 1997;87(5):1075–1081.
32. Mahowald ML, Singh JA, Majeski P. Opioid use by patients in an orthopedics spine clinic. Arthritis Rheum. 2005;52:312–321.
33. Fine PG, Portenoy RK. A Clinical Guide to Opioid Analgesia. New York, NY: McGraw-Hill; 2004.
34. Yeh SY, Gorodetzky CW, Krebs HA. Isolation and identification of morphine-3 and 6-glucuronides, morphine 3,6 diglucuronide, morphine 3 ethereal sulfate, normorphine and normorphine 6-glucuronide as morphine metabolites in humans. J Pharm Sci. 1977;66:1288–1293.
35. Marco CA, Plewa MC, Buderer N, Black C, Roberts A. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial. Acad Emerg Med. 2005;12:282–288.
36. Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain. 1997;73:151–157.
37. Otton SV, Schadel M, Cheung SW, Kaplan HL: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. J Clin Therapeut. 1993;54:463–472.
38. Combunox [package insert]. St Louis, MO: Forest Pharmaceuticals Inc.; 2004.
39. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol. 2001;41:500–506.
40. Mahler DL, Forrest WH. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology. 1975;42:602–607.
41. Inturrisi C, Portenoy R, Stillman M, et al. Hydromorphone bioavailability and pharmacokinetic-pharmacodynamic relationships. Clin Pharm Ther. 1988;43:162–169.
42. Keeri-Szanto M. Anesthesia time/dose curves IX: the use of hydromorphone in surgical anesthesia and post operative pain relief in comparison to morphine. Can Anesth Soc J. 1976;23:587–595.
43. Ritschel WA. Absolute bioavailability of hydromorphone after oral and rectal administration in humans. J Clin Pharmacol. 1987;27:647–653.
44. Babul N. Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10(3):184–186.
45. Peng PW, Sandler AN. Fentanyl for postoperative analgesia: a review. Anesthesiology. 1999;90:576–599.
46. Sinatra RS, Harrison DM, Hyde N. Oxymorphone revisited. In: Katz R, ed. Essays in Anesthesiology. Vol. 8. 1988:208–215.
47. Opana ER(R) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc;). 2005.
48. Anderson A, Saiers JH, Abram S, Schlicht C. Accuracy in equianalgesic: dosing conversion dilemmas. J Pain Symptom Manage. 2001;21:397–406.
49. Wadam EF, Bigelow GE. Johnson RE, Nuzzo PA, Haigney MC. Qt interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469–2475.
50. Latta K, Ginsberg B, Barken K. Meperidine: a critical review. Am J Therapeut. 2002;9:53–68.
51. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD. Kappa-opioids produce significantly greater analgesia in women than in men. Nat Med. 1996;2:1248–1250.
52. Sinatra RS, Sramcik J. Tramadol: its use in pain management. In: Hines RL, ed. Anesthesiology Clinics of North America. Vol. 2. Philadelphia, PA: Saunders, 1998;53–69.
53. Dayer P, Desmules J, Collart L. Pharmacology of tramadol. Drugs. 1997;53(Suppl 2):18–24.
54. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving methadone or burenorphine therapy. Arch Int Med. 2006;144:127–134.
55. Sinatra RS, Torres J, Bustos AM. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg. 2002;10:117–129.
56. Sinatra RS. Treatment guidelines and unpublished observations. Yale University Pain Management Service 2007.
57. Coda BA, Tanaka A, Jacobson RC: Hydromorphone analgesia after intravenous bolus administration. Pain. 1997;71:41–48.
58. Sinatra RS, Harrison DM. A comparison of oxymorphone and fentanyl as narcotic supplements in general anesthesia. J Clin Anesth. 1989;1:253–258.
59. Sinatra RS, Lodge K, Sibert K, et al. A comparison of morphine, meperidine, and oxymorphone as utilized in patient-controlled analgesia following cesarean delivery. Anesthesiology. 1989;70:585–590.
60. Richlin DM, Reuben SS. Postoperative pain control with methadone following abdominal surgery. J Clin Anesthes. 1991;3:112–116.
61. Chui PT Gin T. A double blind randomised trial comparing postoperative analgesia after perioperative loading doses of methadone or morphine. Anesthesia Intensive Care 1992;20:46–51.
62. Shir Y, Rosen G, Zeiden A, Davidson M. Methadone is safe for treating hospitalized patients. Can J Anesthes. 2001;48:1109–1113.
63. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232.
64. Mitra S, Sinatra RS: Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology. 2004;101:212–227.
65. Guinard JP Maurocordatos P Carpenter RL: A randomized comparison of intravenous versus lumbar and thoracic epidural infusions of fentanyl after Thoracotomy. Anesthesiology. 1992;77:1108–1115.
66. Abrahamsson J, Niemand D, Olsson AK, Tornebrandt K. Buprenorphine (Temgesic) as a perioperative analgesic: a multicenter sudy. Anaesthesist. 1983;32(2):75–79.
67. Ho ST, Wang JJ, Liu HS, Tzeng JI, Liaw WJ. The analgesic effect of PCA buprenorphine in Taiwan's gynecologic patients. Acta Anaesthesiol Sin. 1997;35(4):195–199.
68. Bullingham RE, McQuay HJ, Dwyer D, Allen MC, Moore RA. Sublingual buprenorphine used postoperatively: clinical observations and preliminary pharmacokinetic analysis. Br J Clin Pharmacol. 1981;12(2):117–122.
69. McCormack JP, Warnier CB, Levine M, Glick N. A comparison of oral dosed morphine sulfate and on demand IM morphine in the treatment of postoperative pain. Can J Anesthes. 1993;40:819–824.
70. Silvasti M, Rosenberg P, Seppala T, Svartling N, Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand. 1998;42:576–580.
71. Singla N, Pong A, Newman K. Combination oxycodone 5mg/ibuprofen 400mg for the treatment of pain after abdominal surgery in women. Clin Therapeut. 2005;27:45–57.
72. Palangio M, Wideman GL, Keffer M, Landau CJ. Combination hydrocodone and ibuprofen versus oxycodone and acetaminophen in the treatment of postoperative obstetric or gynecologic pain. Clin Therapeut. 2000;22:600–612.
73. Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102:1249–1260.
74. Aqua K, Gimbel JS, Singla N, Ma T, Ahdieh H. Efficacy and tolerability of oxymorphone IR, for acute postoperative pain after abdominal surgery. Clin Therapeut. 2007;29:1000–1012.
75. Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg. 2004;99:1472–1477.
76. McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8:181–186.
77. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin. 2004;20:911–918.
78. Reuben SS, Connelly NR, Maciolek H. Postoperative analgesia with controlled release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg. 1999;48:1286–1291.
79. Ginsberg B, Sinatra RS, Adler LJ, et al. Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. Pain Med. 2003;4(1):31–38.
80. Fricke JR, Karim R, Jordan D, Rosenthal N: A double-blind single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets and placebo after oral surgery. Clin Ther. 2002;24:953–968.
81. Gordon D, Stevenson K, Griffie J, et al. Opioid equianalgesic calculations. J Palliat Med. 1999;2:209–221.
82. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542–2554.
83. Wheeler M, Oderda GM, Asburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain. 2002;3:159–180.
84. Zofran [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004.
85. National Institutes of Health. The NIH Guide: New Directions in Pain Research I. Washington, DC: U.S. Government Printing Office; 1998.
86. Mather LE, Woodhouse A, Ward ME, Farr SJ. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis. Br J Anaesth. 1998;46:37–43.
87. Romberg R, van Dorp E, Hollander J et al. A randomized double-blind placebo-controlled pilot study of morphine-6-glucoronide for postoperative pain relief after knee replacement surgery. Clin J Pain. 2007;23:197–203.